Skip to main content

Table 1 Characteristics of patients and platforms in included studies.

From: Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer

Data set chip # probes Patients, country, nodal statusa outcomeb Adjuvant systemic treatmentc
HUMAC [1] spotted
oligonucleotides
29K n = 60, DK
N-, low-malignant
metastasis nil
Huang [2] Affymetrix
95av2
12K n = 52, Taiwan
N+
relapse ct
Sotiriou 2003 [3] Spotted
cDNA
7.6K n = 99, UK
N+/N-
relapse et, ct
Sotiriou 2006 [4] Affymetrix
HG-133A
22K n = 179 S (Uppsala), UK
N+/N-
dm et
Rotterdam [5] Affymetrix
HG-133A
22K n = 286, NL
N-
dm nil
Amsterdam [6] Rosetta 25K n = 295, NL
N+/N-
dm nil, ct, et
Uppsala [7] Affymetrix
HG133A+B
44K N = 236, S (Uppsala)
N+/N-
death from breast cancer nil, ct, et
Stockholm [8] Affymetrix
HG-133A+B
44K n = 159, S (Stockholm)
N+/N-
relapse nil, ct, et
  1. a: n, number of patients included; N+, positive nodal status; N-, negative nodal status; DK, Denmark; UK, United Kingdom; NL, the Netherlands; S, Sweden.
  2. b: dm, distant metastasis,
  3. c: ct, chemotherapy, et: endocrine therapy